LIBTAYO demonstrated meaningful tumor reduction in clinical trial patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who were not candidates for curative surgery or curative radiation1,2

Patient responses

These are examples from the 47.2% of patients (43.5% PR, 3.7% CR) who had an objective response (defined as PRs + CRs) in clinical trials. Individual patient responses may vary.

Partial response
  • laCSCC
  • Not a candidate for curative surgery or curative radiation
  • 70-year-old male
Auricular lesion
Screening
Image of auricular lesion at the time of screening
After 8 weeks
Image of auricular lesion after 8 weeks of LIBTAYO treatment
After 24 weeks
Image of auricular lesion after 24 weeks of LIBTAYO treatment
After 32 weeks
Image of auricular lesion after 32 weeks of LIBTAYO treatment
Auricular lesion (enlarged view)
Screening
Enlarged image of auricular lesion at the time of screening
After 8 weeks
Enlarged image of auricular lesion after 8 weeks of LIBTAYO treatment
After 24 weeks
Enlarged image of auricular lesion after 24 weeks of LIBTAYO treatment
After 32 weeks
Enlarged image of auricular lesion after 32 weeks of LIBTAYO treatment
Partial response
  • laCSCC
  • Not a candidate for curative surgery or curative radiation
  • 57-year-old male
Partial response
  • laCSCC
  • Not a candidate for curative surgery or curative radiation
  • 96-year-old female
Partial response
  • mCSCC
  • 85-year-old male
Partial response
  • mCSCC
  • 83-year-old male
Metatarsal lesion
Screening
Image of metatarsal lesion at the time of screening
After 8 weeks
Image of metatarsal lesion after 8 weeks of LIBTAYO treatment
After 16 weeks
Image of metatarsal lesion after 16 weeks of LIBTAYO treatment
After 32 weeks
Image of metatarsal lesion after 32 weeks of LIBTAYO treatment
Partial response
  • mCSCC
  • 66-year-old male
Complete response*
  • laCSCC
  • Not a candidate for curative surgery or curative radiation
  • 65-year-old male
  • *Defined as complete healing of prior cutaneous involvement; required biopsy to confirm CR.1
  • CR, complete response; laCSCC, locally advanced CSCC; mCSCC, metastatic CSCC; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization.
  1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC.
  2. Data on file. Regeneron Pharmaceuticals Inc.